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Abstract Systemic sclerosis (SSc) is a chronic fibrosing dis-
ease characterized by vasculopathy, autoimmunity, and an ac-
cumulation of collagen in tissues. Numerous studies have
shown that compared to healthy or diseased controls, the
peripheralbloodmononuclearcells(PBMC)frompatients with
SSc produce a variety of cytokines or proliferate when cultured
with solubilized type I collagen (CI) or constituent α1(II) and
α2(I) polypeptide chains. The purpose of this study was to
determine whether PBMC isolated from patients with SSc and
cultured in vitro with soluble CI elaborated soluble mediators
that inhibit the production of collagenase (i.e., matrix metal-
loproteinase, MMP-1) by fibroblasts. Supernatants of CI-
stimulated PBMC from juvenile and adult diffuse cutaneous
(dc)SSc patients significantly reduced MMP-1 production by
SSc dermal fibroblasts, while supernatants of CI-stimulated
PBMC from patients with localized scleroderma (LS) did not.
CI-stimulated PBMC culture supernatants from patients with
dcSSc in contrast to patients with LS exhibited increased
levels of platelet-derived growth factor (PDGF)-AA, PDGF-
BB,TNF-α,IL-13,andEGF.ProlongedcultureofSScdermal
fibroblasts withrecombinant PDGF-BBorIL-13 inhibited the
induction of MMP-1 in response to subsequent TNF-α stim-
ulation. These data suggest that therapies aimed at reducing
these cytokines may decrease collagen accumulation in SSc,
preventing the development of chronic fibrosis.
Keywords IL-13.Diffuse.Localizedscleroderma.MMP-1.
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Introduction
Scleroderma “fibrosis of the skin” spectrum disorders
include localized scleroderma (LS) variants and systemic
sclerosis (SSc) the latter of which is further divided into
diffuse cutaneous (dc)SSc, limited cutaneous (lc) SSc, and
SSc sine scleroderma. The forms of SSc are differentiated
primarily on the basis of the pattern of skin involvement,
autoantibody association, and characteristics of internal
organ involvement [1]. The main clinical differences
between LS and SSc are the absence in the former of
sclerodactyly, Raynaud's phenomenon, absence of wide-
spread vasculopathy, nail fold capillary changes, and inter-
nal organ fibrosis. Five subtypes of LS or morphea are
recognized by Peterson et al. and include “plaque,”“ gener-
alized,”“ bullous,”“ linear,” and “deep” [2]. The morphea
classification of Laxer and Zulian [3] adds additional
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includes a combination of two or more subtypes in the same
patient. Immunologic tests show that although autoantibod-
ies are highly prevalent in both LS and SSc, they differ in
prevalence and antigen specificity in these major divisions
of scleroderma spectrum disease. For example, antinuclear
antibodies are present in only 20% to 80% of patients with
LS and in >90% of patients with SSc [4, 5]. Moreover, anti-
topoisomerase II alpha antibody is present in up to 85% of
patients with LS and in 14% of patients with SSc [4].
In this present study, we show profound differences in the
immune responses of patients with dcSSC compared to
patients with LS. Peripheral blood mononuclear cells
(PBMC) from patients with dcSSc, but not patients with
LS, cultured in vitro with soluble CI or α1(I) generate
cytokine/growth factor-rich supernatants. These supernatants
induce a reduction in matrix metalloproteinase (MMP)-1 pro-
duction,whenadded to culturesofSSc dermalfibroblasts, but
not to normal donor dermal fibroblast lines. We hypothesize
that T cells from patients with dcSSc are activated by CI to
producecytokinesthatactonfibroblaststoreducesynthesisof
MMP-1. A decrease in the skin fibroblast's ability to synthe-
size MMP-1 could shift the balance of collagen metabolism
toward collagen excess resulting in fibrotic lesions.
In these studies, PBMC from patients with dcSSc or LS
were cultured with or without CI, and the harvested super-
natants were added to cultures of SSc fibroblasts to evaluate
the effects on MMP-1 production. We found that long-term
exposure to supernatants that had been generated by cultur-
ing CI-stimulated PBMC from adult or pediatric patients
with dcSSc caused a significant decrease in the production
of MMP-1 by SSc fibroblasts. In contrast, long-term expo-
sure of SSc fibroblasts to supernatants from CI-stimulated
PBMC from patients with LS did not induce suppression of
MMP-1 production by tumor necrosis factor alpha (TNF-α)-
stimulated dcSSc fibroblasts. These data suggest that thera-
pies aimed at reducing the suppression of MMP may
decrease collagen accumulation in skin and vital organs of
patients with SSC, preventing the development of chronic
fibrosis. Moreover, the results of this study may help eluci-
date the pathogenesis of impaired MMP-1 production by
fibroblasts in SSc.
Results
Inhibition of MMP-1 production by dcSSc dermal fibroblasts
chronically exposed in vitro to pooled culture supernatants
from CI-stimulated PBMC from patients with dcSSc To
determine whether cytokine/growth factors present in super-
natants from culture of CI-stimulated SSc PBMC would
effect a change in MMP-1 production by dermal fibroblasts,
we obtained PBMC from ten adult patients with dcSSc and
stimulated them in vitro with CI or medium alone for 6 days.
The harvested supernatants were pooled and added at 30%
v/v to a culture of dermal fibroblasts from normal donors
and from involved skin of patients with dcSSc for 14 days as
described in the Patients and methods section, and MMP-1
production in response to TNF-α stimulation was assessed.
As shown in Table 1, culture of dcSSc fibroblasts for
14 days with supernatants from CI-stimulated adult dcSSc
PBMC resulted in significant reduction in MMP-1 protein
produced in response to TNF-α stimulation. Compared to
normal fibroblasts, production of MMP-1 was also reduced
in the dcSSc fibroblast cultures not stimulated with TNF-α
but cultured for 14 days with CI-stimulated PBMC from
patients with dcSSc. In contrast, fibroblasts from normal
donors cultured for 2 weeks with the same pooled super-
natants from CI-stimulated dcSSc PBMC and stimulated
with TNF-α showed an actual enhancement of MMP-1
(Table 1).
Since the spectrum of scleroderma can range from very
minimal involvement (LS) to extensive fibrosis (dcSSc), it
was of interest to compare the effect of supernatants from
the culture of PBMC from patients with LS to supernatants
from the culture of PBMC from patients with dcSSc on
MMP-1 production by SSc fibroblasts. In order to determine
the variability among individual patients, we cultured
PBMC with and without CI for 6 days and studied the effect
of each individual donor PBMC supernatant on a single
dcSSC dermal fibroblast line (SSc008) that became respon-
sive (after subpassage 4) to MMP-1 upregulation by TNF-α.
PBMC from four dcSSc patients (one juvenile and three
adults) and five juvenile patients with LS were cultured with
or without native CI for 6 days. The harvested supernatants
from the culture of PBMC from each of these patients were
added at 30% v/v to cultures of dermal fibroblasts (SSc008)
for 21 days with fresh media and PBMC supernatant added
e v e r y3d a y s .A f t e r2 1d a y s ,T N F - α was added to the
cultures of SSc008 fibroblasts, to stimulate production of
MMP-1. As illustrated in Fig. 1, the SSc 008 fibroblast line
produced significantly less MMP-1 after being cultured for
21 days with CI-stimulated supernatants from dcSSc patients
compared to fibroblasts cultured with CI-stimulated super-
natants from LS patients.
Cytokine profile for CI-stimulated PBMC supernatants
from juvenile and adult dcSSc The inhibition of MMP-1
described above isverylikelyinduced by cytokines orgrowth
factors secreted by peripheral blood cells. In order to deter-
mine the cytokine profile of supernatants from culture of
CI-stimulated dcSSc PBMC, we pooled CI-stimulated PBMC
culture supernatants from ten adult patients with dcSSc and
incubatedthesesupernatantsonRayBioplexmembranearrays
to test for presence of individual cytokines/growth factors.
The pooled supernatants were tested on three different
974 Clin Rheumatol (2012) 31:973–981cytokine or growth factor arrays and were found to be abun-
dant in platelet-derived growth factor (PDGF)-AA, PDGF-
BB, PDGF-AB, epidermal growth factor (EGF), insulin-like
growth factor binding protein 2 (IGFBP-2), hepatocyte
growth factor (HGF), macrophage colony stimulating factor
receptor (MCSFR), and interleukin-13 (IL-13) when com-
pared with the culture medium alone (Fig. 2). We further
evaluated the cytokine profile of supernatants from CI-
stimulated PBMC from one pediatric dcSSC patient (Fig. 3,
P003) and two pediatric LS patients (Fig. 3, P001, P002). We
cultured PBMC with CI for 6 days from these patients, har-
vested the supernatant, and incubated these supernatants on
RayBioplex membrane arrays as per manufacturer's instruc-
tions. As shown in Fig. 3, the cytokine profile of supernatants
from CI-stimulated PBMC from the juvenile dcSSc patient
revealedanincreaseinPDGF-AA,PDGF-BB,IL-13,TNF-α,
and EGF when compared to the supernatant from CI-
stimulated PBMC from patients with LS. Although the
numbers are small, the PBMC from the dcSSC patient clearly
secreted greater amounts of PDGF-AA, PDGF-BB, IL-13,
TNF-α, and EGF when compared to supernatants collected
from the culture of CI-stimulated PBMC from LS patients.
These results compare favorably to the cytokine profile in
supernatants from the culture of CI-stimulated PBMC from
adult patients with dcSSc (Figs. 2 and 3).
Effects of long-term incubation of SSc dermal fibroblast
with profibrotic cytokines In a separate experiment,
PDGF-AA, PDGF-BB, IL-13, and EGF were added for
14 days individually at varying doses to cultures of SSc
fibroblasts to assess their effect on MMP-1 production
induced by TNF-α. Although multiple concentrations were
tested, the data shown in Fig. 4 illustrate the most effective
dose for each cytokine. Long-term exposure of SSc 008
fibroblasts to PDGF-BB and IL-13 significantly inhibited
MMP-1 production when the fibroblasts were subsequently
stimulated with TNF-α. These data suggest that each of
these cytokines may be responsible for the inhibitory effect
on fibroblast MMP-1 production induced by supernatants
from CI-stimulated PBMC from patients with dcSSc. In
contrast, long-term exposure of SSc 008 fibroblasts to
PDGF-AA and EGF resulted in enhanced TNF-α stimula-
tion of MMP-1 production (Fig. 4). Although EGF is known
to upregulate TGF-β via PI 3-kinase/Akt signaling pathway
in dermal fibroblasts [6], the upregulation of TGF-β by EGF
in the present experiments would not impact MMP-1 pro-
duction, as activation of latent TGF-β does not occur spon-
taneously in culture, and active TGF-β suppresses MMP-1
production by fibroblasts [7].
Discussion
Our results show that soluble mediators from PBMC from
patients with dcSSc inhibit collagenase expression in cultured
SSc dermal fibroblasts. Supernatants of soluble CI-stimulated
PBMC from dcSSc patients exerted profound suppression of
productionofMMP-1bySScfibroblasts.Pooledsupernatants
from a group of adult dcSSc patients and individual super-
natants from juvenile and adult dcSSc patients significantly
reduced the expression of MMP-1 by SSc fibroblasts. Sup-
pression of constitutive production as well as TNF-α-
stimulated production of MMP-1 by SSc fibroblasts was
observed when these fibroblasts were chronically exposed to
supernatants from CI-stimulated dcSSc PBMC. In contrast,
prolonged culture of SSc fibroblasts with supernatants of CI-
stimulated PBMC from patients with LS did not induce the
MMP-1 suppressive phenotype in SSc fibroblasts.
TNF-α inhibits collagen synthesis and increases synthe-
sis of MMP-1 when added to cultures of normal human
Table 1 Effect of supernatant from type I collagen-stimulated PBMC (from patients with dcSSc) on MMP-1 production by dcSSc and normal
fibroblasts
Additions for 48 h dcSSc fibroblast lines Mean ± SE Normal donor fibroblast
lines
Mean ± SE P value
Fibroblasts cultured with medium 004 008 1685 1822 1 3 2603 6858
PBS
a 4 18 69 38 32±14 5 15 60 29 27±12 NS
b
TNF-α (5 ng/ml) 100 100 100 100 100 100 100 100 100 100
Fibroblasts cultured with 30% v/v
CI-stimulated dcSSc PBMC supernatant
PBS
a 2 15 27 23 17±5 125 69 92 22 77±22 0.036
b
TNF-α (5 ng/ml)
a 54 60 64 34 53±7 578 413 210 106 327±105 0.041
c
MMP1 was measured by Western blot using pooled supernatants of CI-stimulated PBMC from ten dcSSc patients. The pooled PBMC supernatants
were added at 30% v/v to cultures of normal and dsSSc fibroblasts for 14 days as described in the “Patients and methods” section. Normal and
dcSSc fibroblasts cultured with pooled (n010) CI-stimulated dcSSc PBMC supernatants (bottom panel) were compared to the same cells cultured
with the medium alone (top panel). The MMP-1 response to TNF-α in the medium alone was arbitrarily set at 100%
aMMP-1 calculated as a percent of that seen with TNF-α stimulation in fibroblasts cultured with the medium alone
bMMP-1 produced by SSc fibroblasts compared to normal dermal fibroblast cell lines following treatment with PBS
cMMP-1 produced by SSc fibroblasts compared to normal dermal fibroblast cell lines following treatment with TNF-α
Clin Rheumatol (2012) 31:973–981 975fibroblasts [8]. Unstimulated PBMC from patients with lc-
or dcSSc in culture produce greater amounts of TNF-α than
PBMC cultured from healthy volunteers, and the most TNF-
α was produced by unstimulated PBMC from patients with
early (<3-year duration) dcSSc [9]. Higher amounts of TNF-
α are also expressed in the skin of patients with SSc [10].
Although TNF-α is abundantly produced in SSc patients,
our data in this report suggest that cytokines produced by
CI-activated PBMC from patients with dcSSc may render
fibroblasts insensitive to TNF-α upregulation of MMP-1
and thereby contribute to dermal fibrosis.
The pathogenesis of fibrosis in LS and SSc is still unre-
solved, but a role for autoimmunity in effecting fibrosis is
suggested by early tissue infiltrates of mononuclear cells
that have the capability of producing an array of cytokines
and growth factors that are known to mediate fibrogenesis.
The histologic features of the lesional skin of patients with
LS and SSc are largely indistinguishable and are character-
ized in the early stages by perivascular infiltration of pre-
dominantly mature lymphocytes, T lymphoblasts, immature
plasma cells, mature plasma cells, fibroblasts, fibrocytes,
fibroblast-like cells, macrophages, undifferentiated mesen-
chymal cells, and monocytes [11]. Later, additional reports
have described the cellular infiltrates more precisely.
Roumm et al. analyzed the infiltrates in the lesional skin
of patients with SSc using monoclonal antibodies to cell
surface markers and found the mononuclear cell (MNC)
infiltrates were composed predominately of activated
CD4
+ and CD8
+ T cells in a ratio of 2.4 to 1, and few B
cells and monocytes were observed [12]. Importantly, in this
larger cohort study of 115 patients with SSc, significant
correlations were observed between the degree of MNC
infiltration and both the degree and progression of skin
thickening [12].
Separate studies have shown that when PBMC from
patients with lc or dcSSc (in contrast to healthy volunteers)
are cultured with soluble CI or constituent α1(I) or α2(I)
chains, there is increased production of cytokines including
IL-2, IL-6, IFN-γ, IL-10; increased production of monocyte
chemoattractants, and increased Tcell proliferation [13–18].
In addition, Warrington et al. labeled PBMC from patients
with lcSSc, dcSSc, and rheumatoid arthritis and healthy
volunteers with carboxyfluorescein diacetate succinimidyl
ester (CFSE) and cultured these CFSE-labeled PBMC for
14 days with and without soluble native bovine CI and β1,
two chains [dimers formed by α1(I) and α2(I)] [19]. Anal-
ysis by flow cytometry showed a T cell proliferative
response to these CI α chains occurring in 32% of SSc
patients but only in 3.6% healthy volunteers (1 of 19 vol-
unteers) and in 0% RA patients (0 of 9) [19]. The prolifer-
ating T cells expressed CD4
+, activated (CD25
+) memory
(CD45 RO
+) phenotype [19]. The T cell lines generated by
prolonged culture (20–30 days culture) of sorted CI-reactive
Tcells with CI, irradiated autologous PBMC, and IL-2 were
analyzed after resting for 10 days and then stimulated for
72 h with plate-bound anti-CD3 and anti CD28. These Tcell
lines then produced abundant Th1 cytokines, IFN-γ, IL-2,
TNF-α, lower amounts of Th2 cytokines (IL-4, IL-6, and
IL-10), and abundant chemotactic chemokine IL-8 [19].
While this study does not establish whether the dimin-
ished production of MMP-1 that we have observed is due to
Tcell autoimmunity to CI or due to a costimulatory effect of
CI on activated T cells, we favor an antigenic role of CI in
triggering production of cytokines. We have previously
shown that CI-specific T cell clones can be grown from
peripheral blood of SSc patients [19]. Moreover, the fact
Fig. 1 The effect of juvenile and adult dcSSc and LS PBMC super-
natants on MMP-1 production by SSc fibroblasts. PBMC isolated from
patients with dcSSc (n04; solid bars) and LS (n05; hatched bars)
were stimulated with and without CI for 6 days, and the individual
supernatants were tested for their effect on the MMP-1 production by
SSc fibroblasts. Dermal fibroblasts from a patient with SSc (SSc008)
were cultured for 21 days each with PBMC supernatants with (a) and
without CI (b) after stimulation with TNF-α for 24 h. The amount of
MMP-1 accumulating in the culture supernatants is shown measured
by Western blot calculated as a percentage of MMP-1 from fibroblasts
that were not co-cultured with PBMC supernatant, but were stimulated
with TNF-α (control). Results were confirmed by ELISA (not shown).
Results are expressed as mean±SEM for MMP-1 content of the medium
from the fibroblast cultures
976 Clin Rheumatol (2012) 31:973–981that soluble CI was used rather than plate-bound CI in the
PBMC culture favors the concept that CI functions as an
antigen, which triggers the production of cytokines which
cause SSc fibroblasts to assume a phenotype of impaired
MMP-1 production.
The pathogenesis of SSc is marked by the overabundance
ofcollagenandskinfibrosiswhere collagenfibersaccumulate
in the dermis. Uncontrolled production of collagen and other
extracellular matrix proteins produced by fibroblasts contrib-
utes to the fibrosis [20]. MMP-1 is the major proteinase
involved in the degradation of CI and CIII. Although
decreases in MMP-1 in fibroblasts from patients with early
SSc have been reported [21], the results have been controver-
sial [22]. Our data support the concept that an important
component of the pathogenesis of SSc is the diminished
capacity for production of MMP-1 by fibroblasts. Our data
areuniquein indicating that the reductionoffibroblastMMP-1
is mediated by cytokines derived from PBMC stimulated by
CI. It is possible that CI is functioning as an autoantigen or a
co-stimulator of T cells in eliciting these cytokines.
Fig. 2 RayBio Human Cytokine Antibody Array of pooled culture
supernatants from PBMC from ten adult patients with dcSSc stimulat-
ed for 6 days with 10 μg/ml native bovine CI. After 6 days of
incubation of PBMC plus 10 μg/ml CI, culture supernatants were
pooled and analyzed, along with the culture medium alone (complete
DMEM) as a control, in a RayBio Cytokine and Growth Factor
Antibody Array assay. The assays used contained antibodies to 120
cytokines, and receptors and 41 growth factors impregnated in small
circles on membranes along with positive and negative controls. All
antibodies are bound in small duplicate circles on the membranes.
Drawn circles indicate cytokines that were enhanced above the back-
ground. Unstimulated PBMC produce small amounts of cytokines
spontaneously thereby preventing their use as controls
Fig. 3 Cytokine profile supernatants from juvenile dcSSc and LS
PBMC stimulated with CI. PBMC from one patient with dcSSc
(P003) and two patients with LS (P002 and P001) were cultured
individually for 6 days with CI, and the supernatants were collected
and analyzed to be tested using RayBio Cytokine and Growth Factor
Antibody Array assay. The data points represent individual patients.
The patient with dcSSC had increased PDGF-AA, PDGF-BB, IL-13,
TNF-α, and EGF as compared to PBMC from LS patients (P002 and
P001). Comparisons are made to the positive endogenous control
provided by the manufacturer
Clin Rheumatol (2012) 31:973–981 977The expression of IL-13 and its receptor complex is
increased in SSc skin samples, correlating with modified
Rodnan skin scores (Aliprantis; ACR 2010) and with nail
fold capillary patterns [23–25]. Our studies demonstrate that
pooled supernatants from adult SSc PBMC co-cultured with
CI contain significant levels of many profibrotic cytokines
compared to controls (PDGF-AA, PDGF-BB, PDGF-AB,
EGF, IGFBP-2, HGF, MCSFR, and IL-13) [6, 26–29]. Our
studies of pediatric patients with SSc have shown that CI
induces increased expression of PDGF-AA, PDGF-BB,
EGF TNF-α, and IL-13. The overlap of cytokines found in
juvenile and adult SSc compared to that seen in localized
disease may in fact be reflective of severity of skin and
organ involvement between these two diseases. Moreover,
the functional importance of these cytokines is demonstrated
by our results that prolonged incubation of PDGF-BB and
IL-13 significantly inhibited TNF-α, induced MMP-1 pro-
duction by SSc dermal fibroblasts, and highlight the impor-
tance of these cytokines in dcSSc. Together, the interaction
of PBMC with CI and the elicited cytokines stimulates a
pathway inherent in SSc fibroblasts that inhibits MMP-1
expression and contributes to the fibrosis in this disease.
In the present study, we have shown that cytokines pro-
duced by CI-stimulated PBMC from patients with dcSSc
suppress MMP-1 production. These data suggest a role for
activation of lymphocytes and/or monocytes in a subgroup
of patients with dcSSc and suggest a cytokine-mediated
pathway involved in the pathogenesis of the extensive
fibrosis seen in these patients. Since we have shown that
exposure to oral CI may benefit late-phase dcSSc, our new
results have important implications for future treatments for
SSc [30].
Patients and methods
Patient population This study was conducted using proto-
cols approved by the Institutional Review Board of partic-
ipating institutions. The Declaration of Helsinki protocols
were followed; patients gave their written informed consent.
Juvenile patients with dcSSc (ages 16 years or less) were
included in this study who met the PREs/ACR/EULAR
classification of juvenile systemic sclerosis [31]. Adult
patients (aged 18–70) met the American College of Rheu-
matology preliminary criteria for diagnosis of SSc. Patients
with LS met the classification criteria for morphea or linear
scleroderma [2, 32].
Preparation of bovine native CI and α1(I) chains Native CI
was isolated and purified from fetal bovine skin as previ-
ously described [33]. Homogeneity of CI and α1(I) was
confirmed using SDS-PAGE and by cyanogen bromide
peptide mapping. The purified CI was dissolved in cold
0.1 M acetic acid at 4 mg/ml and stored frozen at −70°C.
α1(I) was isolated from denatured bovine CI as previously
described [34]. Purified α1(I) was lyophilized and stored
at −20°C in a desiccator.
Specific reagents Human recombinant TNF-α,I L - 1 3 ,
PDGF-AA, PDGF-BB, and EGF were purchased from
R&D systems (Minneapolis, MN). Anti-rabbit IgG was
purchased from GE Healthcare (UK). The antibody to hu-
man MMP-1 (rabbit) was made to a latent and truncated
peptide, expressed in Escherichia coli, and purified in the
laboratory. MMP-1 was detected by ELISA (R&D systems)
and cytokines by RayBio Human Cytokine Antibody Arrays
(RayBiotech, Inc.).
Production of PBMC culture supernatants Blood samples
were collected in EGTA-containing glass tubes and the
PBMC isolated over Histopaque (Sigma Chemical Co., St.
Louis, MO) cushions by isopynic centrifugation. The
PBMC were plated at 2×10
6 cells per well, cultured in
Dulbeccos's high-glucose modified eagle medium (DMEM)
containing 10% fetal bovine serum (FBS), penicillin
Fig. 4 SSc dermal fibroblasts cultured for 14 days with pro-
inflammatory cytokines followed by stimulation with TNF-α for
24 h. Inhibition of constitutively produced MMP-1 as well as TNF-
α-stimulated MMP-1 production was observed when SSc 008 fibro-
blasts were cultured with PDGF-BB and IL-13 when compared to SSc
fibroblasts cultured with the medium alone for 14 days ± TNF-α.
MMP-1 was increased when fibroblasts were cultured for 14 days with
PDGF-AA or EGF and then stimulated 24 h with TNF-α.* P<0.05
when compared to supernatants from fibroblasts cultured with the
complete medium alone (first bar on the left).
#P<0.05 when com-
pared to supernatants from fibroblasts cultured with the complete
medium plus TNF (second bar from the left)
978 Clin Rheumatol (2012) 31:973–981(100 units/ml), streptomycin (100 ug/ml), and 100× Gluta-
max (Invitrogen Corp.) [19] (hereafter called “Complete
DMEM”). Cells were cultured at 37°C with 5% CO2 for
6 days with and without purified bovine collagen α1(I)
(25 μg/ml) after which the supernatants were collected,
pooled, and stored in −80°C until use. In one experiment,
PBMC from ten adult patients with dcSSc were collected
and cultured for 6 days with native bovine CI (10 μg/ml),
prior to pooling and storing at −70°C.
Dermal fibroblast cultures Four normal and four SSc fibro-
blast lines (two from biopsies of lesional and two from non-
lesional skin of dsSSc patients) were grown for 2–3 weeks
in eagle minimum essential medium, with 9% fetal calf
serum (FCS), 100 μ/ml penicillin, 100 μg/ml streptomycin,
and amphotericin B (1 μg/ml) hereafter referred to as “com-
plete medium.” Thirty percent (by volume) of supernatant
from a culture of CI-stimulated dcSSc PBMC (from a pool
of ten adult patients with dcSSc, sterile filtered and ali-
quoted into individual vials) or 30% medium (by volume)
alone or plus native CI (10 μg/ml) of high-glucose DMEM
containing the same lot of FBS used in the SSc PBMC
cultures was added to each plate containing each cell line.
The medium in the cultures was changed every 7 days, and a
new SSc PBMC culture supernatant or medium control
(each 30% by volume) was added at each refeeding. Cells
were then trypsinized and passed into new 100-mm tissue
culture plates and cultured for 3 days in the complete medi-
um. Fibroblasts were then trypsinized and transferred to
Costar tissue culture plates at a density of 10
5 cells/well
and grown for 3 days in the complete medium. The medium
was then changed to the complete medium containing 5%
FBS for 24 h, changed again to a fresh complete medium
with 5% FCS containing either 5 ng/ml human recombinant
TNF-α (R and D Systems, Minneapolis, MN) in PBS con-
taining 0.1% bovine serum albumin (BSA, Sigma) or PBS
with 0.1% BSA as a control. After 48 h, culture supernatants
were harvested. Culture supernatants were assayed by
ELISA or Western blot analysis to quantitate MMP-1 pro-
tein as previously described [35].
Culture of SSc fibroblasts with supernatants from PBMC
cultures Fibroblasts were grown from dermal biopsies from
similar locations on the forearm of normal volunteers or
patients with dcSSc. SSc fibroblast cell line 008 (SSc 008)
passages 5–15, that had regained the ability to synthesize
MMP-1 upon stimulation with TNF-α, was also used for
comparing the effect of the supernatant from the culture of
PBMC from different donors. This SSc fibroblast line,
grown from the fibrotic skin on the volar forearm of a
patient with dcSSc, was resistant to TNF-α stimulation of
MMP-1 synthesis during the first few subpassages but be-
came more responsive to TNF-α after passage. The SSc 008
fibroblasts were plated at 5×10
4 cells/well in Costar 24 well
and grown in high-glucose DMEM containing 10% FCS.
Supernatants from 6-day PBMC cultures were removed
from −80°C storage, allowed to thaw at 37°C, and then
centrifuged at 190 relative centrifugal force for 10 min.
Additions to fibroblast cultures consisted of the following:
collagen alone in complete DMEM (complete DMEM incu-
bated 6 days with 12.5 μl (12.5 μg) of αl(I) without PBMC
in wells), PBMC supernatant (PBMC; DMEM incubated
6 days with PBMC from scleroderma patients), and collagen
supernatant (+CI/PBMC; DMEM incubated for 6 days with
PBMC and 12.5 μl of 12.5 μg α1(I)). The PBMC super-
natants or complete medium was added at 30% v/v to
triplicate well cultures of SSc 08 fibroblasts. The medium
was changed every 3 days for a total of 21 days, then
DMEM supplemented with 5% FBS was placed on the
fibroblasts for 24 h prior to adding TNF-α 5 ng/ml for an
additional 24 h. Fibroblast cultures were then collected and
stored at 4°C until analysis by Western blot or ELISA to
quantitate MMP-1 level. Fibroblasts were harvested for cell
number quantification using CyQuant (Invitrogen, Eugene,
OR).
Analysis of MMP-1 Fibroblast culture supernatants were
analyzed for MMP-1 protein by Western blot analysis or
by ELISA. Supernatants were resolved on 9% SDS-PAGE
and electrotransferred to a PVDF membrane, blocked in 5%
powdered milk in TBS (1 M Tris, pH 7.4; 4 M NaCl;
deionized water) for 1 h, then soaked in primary MMP-1
antibody. The membrane was washed and incubated with
anti-MMP-1 antibody, and then, alkaline phosphatase-
conjugated anti-rabbit IgG was used to visualize immuno-
reactive bands with ECF substrate. Densities were normal-
ized to cell proliferation values (number of cells) and
calculated as a percent of the TNF-α control value (Storm
860 Molecular Dynamics, Sunnyvale, CA, and Typhoon GE
Healthcare Biosciences AB, Sweden) and analyzed using
ImageQuant TL 7.0 (GE Healthcare, Sweden). In some
experiments, human total MMP-1 Duoset (R&D) was used
to quantify MMP-1.
Cytokine analysis Cytokine analysis was performed on
6-day complete DMEM and +CI/PBMC pooled superna-
tants obtained from 6-day culture of PBMC from ten dcSSc
patients cultured with 10 μg/ml native CI using RayBio
Human Cytokine Antibody Arrays VI, 6.1, and VI, 7.1
(RayBiotech, Inc.).
Further analysis was done on CI-stimulated 6-day PBMC
supernatants from two juvenile LS patients and one dsSSc
juvenile patient. For this analysis, membrane arrays were
custom made for by the manufacturer for detection of
PDGF-AA, PDGF-BB, IL-13, TNF-α, EGF, MCSCR,
insulin-like binding protein 2 (IGFBP-2), IL-1β, HGF, and
Clin Rheumatol (2012) 31:973–981 979IL-17. These cytokines were selected based on the prelim-
inary cytokine data obtained from pooled supernatants from
dcSSc patients. All procedures for this part of the experi-
ment were followed according to the manufacturer's instruc-
tions. Each blot of cytokine array membranes was
normalized to irrelevant endogenous controls included on
the blot by the manufacturer to allow comparisons between
blots and analyzed using Typhoon chemiluminescence.
To study the effect of long-term exposure of fibroblasts to
cytokines/growth factors, fibroblasts were plated in 100-mm
tissue culture plates at 4×10
5 cells per plate and then cultured
with human recombinant PDGF-AA, PDGF-BB, IL-13, and
EGF for a total of 14 days. The medium was changed every
72 h with addition of fresh medium containing the specific
cytokine/growth factor. Fibroblasts were passed by trysiniza-
tion and then plated with the complete medium containing
10% FCS in Costar 24-well tissue culture plates at 5×10
4 per
well. These fibroblasts were then grown in the complete
medium for 1 week with medium change every 72 h. Fibro-
blasts were then grown in DMEM containing 5% FBS for
72 h, followed by 24 h with TNF-α stimulation. Human total
MMP-1 Duoset was used to determine MMP-1.
Statistical analysis An all-or-none comparison was made
between groups. ANOVA and Fisher's exact test were used
for statistical analysis due to a small sample size. P<0.05
was considered significant. Data are reported with bars
indicating the standard deviation of the mean.
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